Intranasal drug developer Opiant Pharmaceuticals has signed an exclusive global licensing deal with Aegis Therapeutics for use of Aegis’ Intravail absorption enhancers with Opiant’s opioid antagonists, the company said. No financial terms were disclosed.
Opiant (formerly Lightlake Therapeutics) licensed its intranasal naloxone formulation for the reversal of opioid overdose to Adapt Pharma in 2014. That product is now marketed as Narcan nasal spray.
Opiant is also developing intranasal naloxone for the treatment of eating disorders and for alcohol dependence.
Opiant CEO Roger Crystal commented, “We are fortunate to be able to access Aegis’ proprietary Intravail drug delivery technologies for applications that may benefit patients with addictions and eating disorders. Aegis’ Intravail can improve the absorption of drugs delivered nasally and has been designated generally recognized as safe (GRAS).”
Aegis CEO Edward T. Maggio added, “The Intravail non-invasive absorption enhancement technology is particularly well suited for the treatment of chronic relapsing brain diseases and will help ensure that Opiant Pharmaceuticals maintains its leaderhip position in this field. We are excited to support these important programs.”
Read the Opiant press release.
